Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreatic beta-cell activity describes the physiological processes by which beta cells in the islets of Langerhans synthesize, store, and secrete insulin in response to glucose and other secretagogues, thus playing a central role in glucose homeostasis. These processes are finely regulated by a network of signals, including glucose, incretin hormones (GLP-1), and paracrine factors (e.g., glucagon from alpha cells). Failure, dysfunction, or destruction of beta-cell activity leads to diabetes mellitus. The term does not refer to a single molecule or receptor but to the collective function of these specialized endocrine cells.
Stimulating insulin secretion (e.g., sulfonylureas act on K_ATP channels) Potentiating glucose-stimulated insulin secretion (e.g., GLP-1R agonists via cAMP-PKA signaling) Protecting against beta-cell apoptosis (GLP-1R, DPP-4 inhibitors) Reducing beta-cell stress and promoting survival (experimental agents)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreatic Beta-Cell Activity.